THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSIO

• Conditions: ESSENTIAL HYPERTENSION; MedDRA version: 12.1Level: LLTClassification code 10015488Term: Essential hypertension

• Registration Number: EUCTR2007-000631-25-SE
• Lead Sponsor: KAROLINSKA INSTITUTET

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04-29
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients of either sex and above the age of 18 with mild-to-moderate essential hypertension. All subjects should be previously untreated or have had no antihypertensive or other drug therapy for at least a 4-week period. They can be included provided their blood pressure is >140 mm Hg systolic and/or >90 mm Hg diastolic.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Secondary hypertension is ruled out by physical examination and routine biochemical examinations. No absolute indications for use of the study drugs, or contraindications against the use of the study drugs should be present. Patients with blood pressures > 180/110 mm Hg will not be allowed to participate. No participation in other studies is allowed. Pregnancy and lactation are criteria for exclusion. Premenopausal women should use an established contraceptive method during the study. Patients with present or recent (within 6 months) malignant disorder or antitumoral treatment are excluded.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified